Jinwu Financial News | Hebo Harbour BioMed (02142) announced that the Group has submitted a new drug clinical trial application (IND) for HBM9378 (or SKB378, as described by Sichuan Collenbotai Biomedical Co., Ltd. (06990) and the company's partner that developed HBM9378) to the State Drug Administration. The drug is a wholly human antibody targeting thymic matrix lymphocytogen (“TSLP”) for the treatment of chronic obstructive pulmonary disease (“COPD”).